An update from Arvinas Holding Company ( (ARVN) ) is now available.
On March 11, 2025, Arvinas, Inc. and Pfizer announced positive results from the Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant monotherapy against fulvestrant in patients with ER+/HER2- metastatic breast cancer. The trial met its primary endpoint in the ESR1m population, showing significant improvement in progression-free survival compared to fulvestrant, although it did not achieve statistical significance in the intent-to-treat population. Vepdegestrant was well tolerated, and the trial will continue to assess overall survival as a secondary endpoint. These results may support future regulatory filings and represent a potential advancement in treatment options for patients with advanced breast cancer.
More about Arvinas Holding Company
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC (PROteolysis TArgeting Chimera) platform. The company is advancing several investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin Lymphoma, and ARV-102 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut.
YTD Price Performance: -7.04%
Average Trading Volume: 1,117,650
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.21B
For detailed information about ARVN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com